PTU-associated	ptu-associated	O	O	O	O
vasculitis	vasculitis	O	DISEASE	OTHERS	I
in	in	O	O	O	O
a	a	O	O	O	O
girl	girl	O	O	O	O
with	with	O	O	O	O
Turner	turner	O	DISEASE	OTHERS	I
Syndrome	syndrome	O	DISEASE	OTHERS	I
and	and	O	O	O	O
Graves	graves	O	DISEASE	OTHERS	I
'	'	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Palpable	palpable	O	O	O	O
purpura	purpura	O	O	OTHERS	I
is	is	O	O	O	O
a	a	O	O	O	O
concerning	concerning	O	O	O	O
clinical	clinical	O	O	O	O
finding	finding	O	O	O	O
in	in	O	O	O	O
pediatric	pediatric	O	O	O	O
patients	patients	O	O	O	O
and	and	O	O	O	O
can	can	O	O	O	O
have	have	O	O	O	O
many	many	O	O	O	O
causes	causes	O	O	O	O
,	,	O	O	O	O
including	including	O	O	O	O
infectious	infectious	O	O	O	O
and	and	O	O	O	O
autoimmune	autoimmune	O	O	O	O
processes	processes	O	O	O	O
.	.	O	O	O	O

A	a	O	O	O	O
rare	rare	O	O	O	O
cause	cause	O	O	O	O
,	,	O	O	O	O
drug-induced	drug-induced	O	O	O	O
vasculitis	vasculitis	O	DISEASE	OTHERS	I
,	,	O	O	O	O
may	may	O	O	O	O
result	result	O	O	O	O
from	from	O	O	O	O
the	the	O	O	O	O
production	production	O	O	O	O
of	of	O	O	O	O
antineutrophil	antineutrophil	O	O	O	O
cytoplasmic	cytoplasmic	O	O	O	O
antibodies	antibodies	O	O	O	O
(	(	O	O	O	O
ANCAs	ancas	O	O	O	O
)	)	O	O	O	O
in	in	O	O	O	O
response	response	O	O	O	O
to	to	O	O	O	O
a	a	O	O	O	O
medication	medication	O	O	O	O
.	.	O	O	O	O

We	we	O	O	O	O
report	report	O	O	O	O
a	a	O	O	O	O
girl	girl	O	O	O	O
with	with	O	O	O	O
Turner	turner	O	DISEASE	OTHERS	I
syndrome	syndrome	O	DISEASE	OTHERS	I
and	and	O	O	O	O
Graves	graves	O	DISEASE	OTHERS	I
'	'	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
who	who	O	O	O	O
presented	presented	O	O	O	O
with	with	O	O	O	O
palpable	palpable	O	O	O	O
purpuric	purpuric	O	O	OTHERS	I
lesions	lesions	O	O	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
diagnosis	diagnosis	O	O	O	O
of	of	O	O	O	O
propylthiouracil	propylthiouracil	CHEMICALS	O	OTHERS	I
(PTU)-associated	(ptu)-associated	O	O	O	O
vasculitis	vasculitis	O	DISEASE	OTHERS	I
was	was	O	O	O	O
made	made	O	O	O	O
by	by	O	O	O	O
observation	observation	O	O	O	O
of	of	O	O	O	O
consistent	consistent	O	O	O	O
clinical	clinical	O	O	O	O
features	features	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
detection	detection	O	O	O	O
of	of	O	O	O	O
elevated	elevated	O	O	O	O
ANA	ana	O	O	O	O
and	and	O	O	O	O
ANCA	anca	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
blood	blood	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
the	the	O	O	O	O
observed	observed	O	O	O	O
clinical	clinical	O	O	O	O
resolution	resolution	O	O	O	O
of	of	O	O	O	O
symptoms	symptoms	O	O	O	O
following	following	O	O	O	O
withdrawal	withdrawal	O	O	O	O
of	of	O	O	O	O
PTU	ptu	O	O	OTHERS	I
.	.	O	O	O	O

Subsequent	subsequent	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
persistent	persistent	O	O	O	O
hyperthyroidism	hyperthyroidism	O	DISEASE	OTHERS	I
with	with	O	O	O	O
radioablation	radioablation	O	O	O	O
did	did	O	O	O	O
not	not	O	O	O	O
result	result	O	O	O	O
in	in	O	O	O	O
an	an	O	O	O	O
exacerbation	exacerbation	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
vasculitis	vasculitis	O	DISEASE	OTHERS	I
,	,	O	O	O	O
a	a	O	O	O	O
complication	complication	O	O	O	O
described	described	O	O	O	O
in	in	O	O	O	O
prior	prior	O	O	O	O
case	case	O	O	O	O
reports	reports	O	O	O	O
.	.	O	O	O	O

